Global HIV Programme
The WHO Department of Global HIV, Hepatitis and Sexually Transmitted Infections Programmes leads the development and implementation of the global health sector strategy on the elimination of HIV as a public health threat.
About us

Surveillance of pretreatment HIV drug resistance – treatment-naive infants newly diagnosed with HIV

The surveillance of pretreatment HIV drug resistance among treatment-naive infants newly diagnosed with HIV is particularly relevant in settings where many infants acquire HIV infection. Surveillance provides critical information to support optimal choice of first- and second-line antiretroviral therapy regimens.

The purpose of this surveillance is to assess the prevalence of HIV drug resistance among treatment-naive infants younger than 18 months (regardless of prevention of mother-to-child transmission exposure), who have been newly diagnosed with HIV using early infant diagnosis over a 12-month period.

Toolkit

Generic editable protocol

Cross-sectional survey of pretreatment HIV drug resistance to ARV drugs in infants newly diagnosed with HIV by early infant diagnosis 

English (MS Word, 100 kB)
Spanish (MS Word, 102 kB)

WHO regularly produces a global report on HIV drug resistance threats, prevalence and trends, based on the information shared by countries. Click here to see the reports.